Insider Transactions in Q2 2025 at Keros Therapeutics, Inc. (KROS)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2025
|
Adar1 Capital Management, LLC > 10% Shareholder |
SELL
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,700
-0.02%
|
$112,200
$66.67 P/Share
|
|
Jun 04
2025
|
Jean Jacques Bienaime |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+49.07%
|
-
|
|
Jun 04
2025
|
Mary Ann Gray |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
Jun 04
2025
|
Alpna Seth |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
Jun 04
2025
|
Ran Nussbaum |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
Jun 04
2025
|
Tomer Kariv |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
Jun 04
2025
|
Nima Farzan |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
Jun 04
2025
|
Carl L Gordon |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
Jun 04
2025
|
Julius Knowles |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+44.91%
|
-
|
|
Apr 09
2025
|
Adar1 Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
934,258
+4.51%
|
$8,408,322
$9.86 P/Share
|
|
Apr 04
2025
|
Jasbir Seehra CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
49,367
+14.04%
|
$0
$0.3 P/Share
|